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Scope: Chicken foot proteins have recently been demonstrated by the group
to be a great source of hydrolysates with antihypertensive properties. The aim
of this study was to isolate and identify angiotensin I-converting enzyme
inhibitory (ACEI) peptides from chicken foot hydrolysate Hpp11 and to test
their antihypertensive properties.
Methods and Results: Peptides are separated into fractions according to their
molecular size and hydrophobicity by ultrafiltration and RP-HPLC,
respectively. Subsequent peptide identification in the two fractions that
present the highest ACEI activities is carried out by HPLC-MS. Ten of the
identified peptides are synthesized and five of them show ACEI (IC50) values
lower than 100 µm. The antihypertensive effects of these ACEI peptides after
oral administration is evaluated in spontaneously hypertensive rats. The
peptides AVFQHNCQE and QVGPLIGRYCG exhibit antihypertensive activity
when administered at an oral dose of 10 mg kg−1 body weight. The maximal
decrease in systolic blood pressure is recorded 6 h after their administration
(−25.07 ± 4.21 and −10.94 ± 1.96 mmHg, respectively).
Conclusion: These results suggest that AVFQHNCQE and QVGPLIGRYCG
could be used as functional ingredients with antihypertensive effects,
although it would be necessary to perform bioavailability and clinical studies
to demonstrate their efficiency in humans.
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1. Introduction
In recent years, hypertension has be-
come a public health concern, being one
of the independent risk factor for de-
veloping cardiovascular diseases (CVD),
the leading global cause of death.[1]
It is well known that a reduction in
blood pressure (BP) is beneficial to pre-
vent CVD. In fact, a reduction of 10/5
mmHg in systolic blood pressure (SBP)/
diastolic blood pressure (DBP) signifi-
cantly reduces the relative risk of all ma-
jor cardiovascular outcomes.[2] One of
the main regulatory systems of the BP
is the renin-angiotensin-aldosterone sys-
tem being angiotensin I-converting en-
zyme (ACE, EC 3.4.15.1) the key enzyme
in this system. ACE belongs to a fam-
ily of zincmetallopeptidases and produce
the cleavage of the C-terminal dipeptide
from angiotensin I to release angiotensin
II, a potent vasoconstrictor.[3] The inhibi-
tion of ACE is considered important tar-
get for treatment of hypertension.[4] How-
ever, the administration of synthetic ACE
inhibitors, such as captopril, lisinopril, and enalapril, has been
reported to have adverse side effects.[5] Thus, there has been an
increasing interest in development of the natural antihyperten-
sive compounds and ACE inhibitors as alternative for lowering
BP.[6]
In this sense, bioactive peptides from dietary proteins have
reported a wide range of biological activities,[7,8] including
antihypertensive effect.[9–11] These peptides are enclosed in the
native structure of the proteins and a treatment is needed to
release these bioactive sequences.[12] However, other factors such
as the possible structural changes performed during protein di-
gestion and the suitability to be absorbed in the gastrointestinal
tract could interfere in the peptides final bioactivity in vivo.[13]
Therefore, although bioactive peptides presenting in vitro ACE
inhibitory (ACEI) activity has been extensively reported,[14] the ev-
idence for their beneficial antihypertensive effects has to be based
on the effect after their administration in animal experiments.[15]
Different protein sources have been demonstrated to re-
lease ACEI peptides with BP lowering properties after their
oral administration,[9,11,16] including proteins from chicken
by products.[17] These chicken by products are disposed of as
waste, producing environmental and economic problems.[18,19]
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Therefore, their reuse for the obtainment of bioactive peptides in-
cluding antihypertensive peptides has received great attention.[17]
In this sense, chicken feet, by products of the poultry industry,
have recently been established by our group as an excellent
protein source to obtain hydrolysates with antihypertensive
properties.[20] In fact, the BP lowering effect after short and long-
term administration of a low dose of the chicken foot hydrolysate
Hpp11 have been recently demonstrated in spontaneously hyper-
tensive rats (SHR) and cafeteria-diet fed rats.[21,22] However, the
chicken foot bioactive peptides have not been characterized yet.
Therefore, the aim of the present study was to isolate and identify
the ACEI peptides present in Hpp11. The isolation of the pep-
tides was performed by ultrafiltration followed by two chromato-
graphic steps and their amino acid sequence were identified by
mass spectrometry. The antihypertensive effect of peptides that
exhibited notable ACEI activity was posteriorly proved in SHR.
2. Experimental Section
2.1. Chemicals and Reagents
Chicken feet (Gallus gallus domesticus) were provided by a
local farm (Granja Gai`a, La Riera de Gai`a, Spain). Protamex
solutions (EC 3.4.21.62 and 3.4.24.28, 1.5 AU g−1 from Bacillus
licheniformis and Bacillus amyloliquefaciens) were kindly pro-
vided by Novozymes (Bagsværd, Denmark). ACE (angiotensin
I-converting enzyme, EC 3.4.15.1) was purchased from Sigma-
Aldrich (Madrid, Spain), captopril (PubChem CID: 44093) was
purchased from Santa Cruz Biotechnology (Dallas, TX, USA)
and o-aminobenzoylglicil-p-nitrofenilalanilprolina (o-Abz-Gly-p-
Phe(NO2)-Pro-OH) was provided by Bachem Feinchemikalien
(Bubendorf, Switzerland). The synthesized peptides (LSETVV,
LSGPVKF, AVKILP, VRWEPAPGPV, VGKPGARAPMY,
QVGPLIGRYCG, LGIHPDWQFV, and AVFQHNCQE, purity
grade  90 %) were purchased from Caslo Laboratory ApS
(Kongens Lyngby, Denmark). Acetonitrile and trifluoroacetic
acid were purchased from Sigma-Aldrich. All other chemical
solvents used were of analytical grade.
2.2. Preparation of Chicken Foot Hydrolysate
The chicken foot protein hydrolysate Hpp11 was elaborated us-
ing the commercial enzymatic solution protamex as previously
was described.[20] Briefly, chicken feet were cleaned, crushed,
lyophilized, milled, and sieved using a 2-mm pore size sieve to
obtain a fine chicken foot powder. Chicken foot powder (20 mg
mL−1, w/v) was resuspended in distilled water and incubated for
90 min in a water bath set at 100 °C at 100 rpm. Subsequently,
the protamex enzymatic solution was added at a final concentra-
tion of 2.67 µg mL−1 (enzyme/substrate ratio, 0.4 AU g−1 pro-
tein). Hydrolysis was carried out at 50 °C for 2 h at pH 7.0 in a
MaxQ Orbital Shaker Thermo Scientific (Thermo Fisher Scien-
tific, Waltham, MA, USA). At the end of the reaction, the enzyme
was heat-inactivated (80 °C, 10 min) in a water bath. Then, the
hydrolysate was centrifuged at 10 000 × g for 20 min at 4 °C and
the supernatant was filtered through a 0.45-µm membrane; fi-
nally, the filtrate was collected for analysis.
2.3. Isolation and Identification of ACEI Peptides from Chicken
Foot Hydrolysate
2.3.1. Step I: Protein Separation Based on Protein Molecular
Weight
Hpp11 was subjected to ultrafiltration through two hydrophilic
membranes with cut-off values of 3 and 10 kDa cut-off (Cen-
tripep, Amicon, Inc., Beverly, MA, USA). The obtained fractions
(<3 kDa, 3–10 kDa and >10 kDa) were freeze-dried and kept at
−20 °C until use. The protein concentration and ACEI activity
were tested for each fraction at least in duplicate and used for
fraction selection.
2.3.2. Step II: Peptide Separation Based on Peptide
Hydrophobicity
Semipreparative reverse phase high performance liquid chro-
matography (RP-HPLC) separations of the<3 kDa fraction were
performed on an Agilent Series 1260 HPLC equipped with the
Agilent OpenLab CDSChemStation Edition for LC& LC/MS sys-
tems A.01.04 software for data acquisition (Agilent Technologies,
Santa Clara, CA, USA). A Europa peptide C18 column (25 × 1.0
cm i.d., 5 µm particle size, 120 A˚ pore size) (Teknokroma) was
used. Mobile phase A was a mixture of water-trifluoroacetic acid
(1000:1) and mobile phase B contained a mixture of acetonitrile-
trifluoroacetic acid (1000:0.8). Elution was performed in gradi-
ent mode as follows: initial conditions 0 % B; 0–40 % B, 0–50
min; 40–45 % B, 50–51 min; 45–90 % B, 51–56 min; and 90–
0 % B, 56–57 min. A 10 min post-run was required for column
re-equilibration. The flow rate was set at 4 mL min−1 and analy-
ses were performed at room temperature (RT). Absorbance of the
eluent was monitored at 214 nm. The sample concentration was
10 mg mL−1 (dissolved in water) and the injection volume was
750 µL. Fractions from the HPLC system were freeze-dried and
kept at −20 °C until use. The protein concentration and ACEI
activity were also tested for each fraction at least in duplicate and
used for fraction selection.
The two fractions showing the most potent ACEI activity, F.3
and F.6, were subsequently subjected to a second semiprepara-
tive RP-HPLC separation. The chromatographic conditions were
similar but the elution was performed with a linear gradient of
solvent B in A, going from 10 % to 20 % B over 40 min at RT
or from 20% to 30 % B over 40 min for fractions F.3 and F.6,
respectively. A flow rate of 4 mL min−1 was used in both cases.
The sample concentration was 10 mg mL−1 (dissolved in water)
and the injection volume was 750 µL. The ACEI activity and pro-
tein concentration were determined in all subfractions at least in
duplicate and used for subfraction selection.
2.3.3. Step III: Peptide Identification by HPLC-MS
For peptide identification, the most active hydrolysate subfrac-
tions (F3.3 and F6.6) obtained in the second RP-HPLC separa-
tion were diluted in 0.1 % TFA to a 0.1 mg mL−1 final concentra-
tion. A 10 µL aliquot of each sample was injected into the linear
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trap quadrupole (LTQ) Orbitrap Velos-PRO (Thermo Scientific).
Peptides were loaded onto an EASY-Column (2 cm, ID 100 µm,
5 µm, C18-A1 precolumn) (Thermo Scientific) and then eluted
onto an EASY-Column (10 cm, ID 75 µm, 3 µm, C18-A2 analyt-
ical column) (Thermo Scientific) at a flow rate of 400 nL min−1
on a nanoEasy high-performance liquid chromatography (HPLC)
instrument (Proxeon) coupled to a nanoelectrospray ion source
(Proxeon). The mobile phases used consisted of 0.1 % formic
acid/2 % ACN (solvent A) and 0.1 % formic acid in 100 % ACN
(solvent B). For the F3.3 fraction, the gradient was 0–45 % B over
80 min, from 45–100 % over 20 min and then 10 min at 100 % B.
In contrast, for the F6.6 fraction, the gradient was from 0–35 % B
over 40 min, from 35–100 % over 10 min and then 10 min at 100
% B. All mass spectra were acquired in positive-ion mode. Full-
scan MS spectra were (m/z 50–2000) were acquired with a target
value of 1 000 000 at a resolution of 30 000 at 400 m/z, and the
15most intense ions were selected for collision-induced dissocia-
tion fragmentation in the LTQ with a target value of 10 000 and a
normalized collision energy of 35 %. Precursor ion charge-state
screening and monoisotopic precursor selection were enabled.
Singly charged ions and unassigned charge states were rejected.
Dynamic exclusion was enabled with a repeat count of 1 and an
exclusion duration of 30 s.
Proteome Discoverer 1.4.288 (Thermo) with MASCOT 2.4.1.0
was used to search the IPI chicken 3.81 fasta database (25992 se-
quences). The following database search parameters were used:
peptide tolerance, 10 ppm; fragment ion tolerance, 0.8 Da; no en-
zyme and variable modification, methionine oxidation. During
peptide identification, probability scores greater than the score
fixed by Mascot were considered as significant with a p-value mi-
nor than 0.05. The automatic decoy database search function in
Protein Discover was enabled to allow estimation of the false dis-
covery rate (FDR).
The identified sequences were subsequently chemically syn-
thesized by Caslo Laboratory ApS.
2.4. ACEI Activity
ACEI activity was measured according to Mas-Capdevila et al.[21]
The fluorescence measurements were performed after 30 min
in a multiscan microplate fluorimeter (FLUOstar optima, BMG
Labtech, Offeuburg, Germany). The excitation and emission
wavelengths were 360 and 400 nm, respectively. The software
used to process the data was FLUOstar control (version 1.32 R2,
BMG Labtech).
A nonlinear fit was performed on the experimental data to cal-
culate the 50 % inhibitory concentration values (IC50) with the
PRISM version 4.02 program for Windows (GraphPad Software,
Inc. San Diego, CA, USA). ACEI activity was expressed as a per-
centage (%) or IC50 (µg µL−1 solution). The determination of the
ACEI activity of the samples was performed at least in duplicate.
Data are represented as a mean value ± standard deviation (SD).
Protein content was determined by the bicinchoninic acid
method using the standard Pierce BCA Protein Assay (Ther-
moFisher Scientific). The assay was conducted according to the
manufacturer’s instructions in amicroplate format. A calibration
standard curve was prepared with seroalbumin bovine. Determi-
nation of the protein content was performed at least in duplicate.
The results are expressed as the mean ± SD.
2.5. Measurement of Blood Pressure
Male SHR (17–20 weeks old, weighing 350–400 g) were obtained
from Charles River Laboratories Espan˜a S.A. (Barcelona, Spain).
The animals were singly housed in animal quarters at 22 °C with
a 12 h light–dark period. They were fed with a standard diet based
on chow Panlab A04 (Panlab, Barcelona, Spain) and had access
to tap water ad libitum.
The SBP and DBP in the animals were measured using the
tail-cuff method [23] with a noninvasive BP system model (Letica,
Hospitalet, Barcelona, Spain). The rats were given a single dose
of 10 mg kg−1 body weight (bw) of the synthesized peptides,
including VGKPGARAPMY, QVGPLIGRYCG, AVFQHNCQE,
LSGPVKF, or AVKILP, dissolved in tap water in a total volume of
1.5 mL. Peptides were administered to the SHR by gastric incu-
bation through an acute administration between 9 and 10 in the
morning.
Positive control rats received 50 mg kg−1 bw of captopril, a
known ACE-inhibitor, also dissolved in 1.5 mL of tap water, and
the negative control rats received 1.5 mL of tap water. SBP was
measured in the rats before peptide administration as well as 2,
4, 6, 8, and 24 h post-administration. Before the measurement,
the animals were kept at 38 °C for 10min to detect the pulsations
of the tail artery. The changes in SBP and DBP were expressed
as the differences in these variables before and after the admin-
istration of the different peptides. Data are shown as the mean
values± standard error of the mean (SEM) for a minimum of six
experiments. Before starting the experiment, all animals were ac-
customed to the process with a 2-week training period.
The animal protocol followed in this study was approved by
Spanish Royal Decree 223/1988 and by the Bioethical Committee
of Universitat Rovira i Virgili (reference number 8868 by Gener-
alitat de Catalunya).
Differences between treatments were analyzed by two-way
analysis of variance (two-way ANOVA). All the analyses were per-
formed using IBM SPSS Statistics (SPSS, Chicago, IL, US). Out-
liers were determined using Grubbs’ test. Differences between
groups were considered significant when p < 0.05.
3. Results
3.1. Identification of ACEI Peptides
Hpp11 was first subjected to ultrafiltration through 3 kDa and
10 kDa cut-off membranes to separate the peptides according to
their molecular size. ACEI activity was determined in the follow-
ing three obtained fractions:<3 kDa, 3–10 kDa and>10 kDa. The
percentages of inhibition obtained were 95.98 ± 0.72 for the <3
kDa fraction, 13.25 ± 2.86 for the 3–10 kDa fraction and 30.50 ±
2.24 for the >10 kDa fraction at a protein concentration of 74.2,
78.3, and 41.7 µg mL−1, respectively. The ACEI activity of the
<3 kDa fraction was the most active and the expressed as IC50
was three and a half times higher than activity found for Hpp11
hydrolysate (3.6 µg vs 12.6 µg mL−1) (Figure 1). These results
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Figure 1. Determination of the angiotensin I-converting enzyme inhibitory (ACEI) activity expressed as the IC50 for A) Hpp11 hydrolysate and B) the
Hpp11 hydrolysate<3 kDa fraction. The IC50 values were determined by curve fitting with a nonlinear regression analysis. The experimental data in each
graphic correspond to two different assays in duplicate.
Figure 2. A) Fractionation by RP-HPLC at a semipreparative scale for the <3 kDa fraction obtained from Hpp11. The collected fractions were termed
with F followed by a number (F1–F8). The angiotensin I-converting enzyme inhibitory activity expressed as B) the percentage of inhibition and C) IC50 (µg
mL−1) of the collected fractions from the semipreparative RP-HPLC system. The data are expressed as the mean ± standard deviation for a minimum
of two measurements. The protein contents of the fractions were estimated using the bicinchoninic acid assay.
indicate that the ACEI activity of Hpp11 is mainly due to small
peptides.
The <3 kDa fraction was subjected to semipreparative RP-
HPLC to separate the peptides according to their peptide hy-
drophobicity and eluted as described in Section 2.3.2. The base
peak chromatogram for this fraction can be seen in Figure 2A,
showing that the hydrolysate was a complex mixture of peptides.
Thus, it was divided into eight fractions (named from F1 to F8),
which were collected and lyophilized, and their ACEI activities
were measured (Figure 2A,B). Fractions F2 to F6 showed high
ACEI activity (70 %). The ACEI activity of these selected frac-
tions was also determined and expressed as IC50 values (µg of
protein per mL) to identify the fraction with the largest amounts
of bioactive peptides. Most of the ACEI activity from the <3 kDa
fraction occurred in fractions 3 and 6 (F3 and F6), which showed
IC50  2 µg mL−1 (1.99 and 1.24 µg mL−1, respectively). These
two fractions were further purified by a second RP-HPLC step.
Figure 3A,B shows the RP-HPLC pattern obtained from F3 and
F6. Fraction F3 was subdivided into six new subfractions (from
F3.1 to F3.6) and F6 was subdivided into eight new subfractions
(from F6.1 to F6.8). All fractions showed a specific ACEI activity
12 µg mL−1 (IC50) (Figure 3B–E). However, fractions F3.3 and
F6.6 were remarkably the most active, with IC50 values of 0.83
and 0.86 µg mL−1, respectively (Figure 3D,E).
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Figure 3. Fractionation by RP-HPLC at a semipreparative scale for fractions A) F3 and B) F6 obtained from the first RP-HPLC separation. The collected
subfractions are termed with the name of the original fraction followed by a point and a number. The angiotensin I-converting enzyme inhibitory activity
expressed as C,D) the percentage of inhibition and E,F) IC50 (µg mL−1) of the subfractions from the second separation of F3 and F6, respectively. The
data are expressed as the mean ± standard deviation for a minimum of two measurements. The protein contents of the fractions were estimated using
the bicinchoninic acid assay.
Table 1. Identification of the peptides contained in the obtained RP-HPLC
subfractions showing the highest angiotensin I-converting enzyme in-
hibitory activities.
Fraction Sequencea) Theoretical M.W. MH+ [Da] m/z [Da] Charge
F3.3 VGKPGARAPmYb) 1146.4 1162.59 581.80 2
F3.3 QVGPLIGRYCG 1162.4 1162.61 581.80 2
F3.3 LGIHPDWQFV 1211.4 1211.62 404.54 3
F3.3 AVFQHNCQE 1075.2 1075.47 538.24 2
F6.6 LSETVV 646.7 647.36 324.18 2
F6.6 LSGPVKF 746.9 747.44 374.22 2
F6.6 AVKILP 639.8 640.44 320.72 2
F6.6 VRWEPAPGPV 1107.3 1107.59 554.30 2
a)Amino acids are designated using their one letter codes; b)m = Oxidation of me-
thionine
The analysis of these subfractions by mass spectrometry
allowed the identification of 772 peptides in fraction F3.3 and
248 peptides in fraction F6.6. Eight of these peptides were
subsequently selected and synthesized. Peptide selection was
performed according to their high sign intensity, peptide length,
and amino acid sequence (Table 1). As an example, Figure 4A,B
shows the MS/MS spectrum of ion m/z 538.2 and 554.3 corre-
sponding to the sequences AVFQHNCQE and VRWEPAPGPV,
respectively. The synthesized peptides showed a wide range of
ACEI activity percentages from 0% to 92% (Table 2). From the
eight peptides analyzed, only five peptides showed an ACEI
activity higher than 50 %. Their IC50 values were lower than
100 µm. Two of these peptides stood out for their high ACEI
activity, sequences AVKILP and QVGPLIGRYCG, which showed
IC50 values as low as 7.06 and 11.01 µm, respectively.
3.2. Antihypertensive Activity of the Synthetic Peptides
The antihypertensive effects of the peptides showing the lowest
IC50 values were evaluated in SHR (Figure 5). Prior to oral admin-
istration of the different peptides, SHR presented SBP values of
208.5± 8.0 mmHg and DBP values of 163.3± 4.6 mmHg (n = 6
for each treatment). The SBP and DBP of SHR administered
water did not significantly change during the 48 h duration of the
experiment. As expected, the administration of captopril (50 mg
kg−1 bw) resulted in an important decrease in the SBP of SHR
from 2 h after its administration, with the maximum decrease
(−33.67 ± 1.94 mmHg) observed at 6 h post-administration.
With respect to DBP, captopril administration also produced a
significant reduction, reaching a maximum decrease 4 h post-
administration (−32.97 ± 8.80 mmHg). The antihypertensive
effect was maintained to 48 h after captopril administration.
From the five peptide sequences administered to SHR, in-
cluding VGKPGARAPMY, QVGPLIGRYCG, AVFQHNCQE, LS-
GPVKF, and AVKILP, the peptides AVFQHNCQE and QVGPLI-
GRYCG exerted antihypertensive effects when administered at
10 mg kg−1 bw to SHR (Figure 5A,B). Nevertheless, AVFQH-
NCQE was the most active peptide. The administration of this
peptide produced a significant decrease in both the SBP andDBP
in SHR (−25.07 ± 4.21 mmHg and −17.65 ± 3.24 mm Hg,
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Figure 4. MS/MS spectrum of the doubled charged ions m/z A) 538.2 and B) 554.3. Following sequence interpretation and database searching, the
peptides were identified as AVFQHNCQE and VRWEPAPGPV, respectively. The MS/MS spectra were acquired with linear trap quadrupole-Orbitrap
mass spectrometry. The sequences of these peptides are displayed with the fragment ions observed in the spectra.
Table 2. The angiotensin I-converting enzyme inhibitory activities of the
synthetic peptides expressed as percentages and IC50 values.
Fraction Sequence Peptide
concentration [µm]
ACEI activity
%a) IC50b)
[µm]
F3.3 VGKPGARAPmY 174.5 75.8 ± 0.06 29.7
F3.3 QVGPLIGRYCG 161.4 87.2 ± 0.33 11.0
F3.3 LGIHPDWQFV 137.6 0.0 ± 0.0 >137.6
F3.3 AVFQHNCQE 142.8 90.4 ± 0.02 44.8
F6.6 LSETVV 128.9 12.9 ± 0.71 >515.4
F6.6 LSGPVKF 122.7 58.4 ± 4.27 80.9
F6.6 AVKILP 101.4 91.8 ± 0.03 7.1
F6.6 VRWEPAPGPV 150.5 21.7 ± 2.30 >150.0
a)Percentage of ACEI activity showed at the indicated protein concentration.;
b)Concentration of peptide needed to inhibit 50 % of the original ACE activity.
respectively). The maximum decrease in SBP caused by AVFQH-
NCQE was observed 6 h post-administration while the maxi-
mum decrease in DBP was registered at 2 h. BP returned to
initial values 24 h after administration. Regarding QVGPLI-
GRYCG, it was also observed that this peptide produced a sig-
nificant decrease in SBP (−10.94 ± 1.96 mm Hg) 6 h post-
administration. Nevertheless, no significant reduction in DBP
was observed when this peptide was administered. The BP of
SHR after VGKPGARAPMY, LSGPVKF, and AVKILP adminis-
tration did not change during the experiment (data not shown).
4. Discussion
It is well-known that the hydrolysis of dietary proteins generates a
large number of peptides, including some with potentially bioac-
tive activities.[24] In this sense, the hydrolysis of chicken protein
frombyproducts has been reported to be a good source for obtain-
ing ACEI and antihypertensive peptides.[17] In a previous study
performed by our group, chicken feet dissolved in water were
heated at 100 °C and hydrolyzed using protamex to obtain the
hydrolysate Hpp11, which was able to reduce BP when adminis-
tered to SHR at low doses.[20] The bioactivity of this hydrolysate
was assumed to be due to the presence of specific peptide se-
quences in Hpp11. Thus, the aim of this study was to identify the
antihypertensive peptides present in the hydrolysate Hpp11. To
assess this objective, Hpp11 was subjected to ultrafiltration using
Figure 5. Decrease in the systolic blood pressure (SBP) in spontaneously hypertensive rats after the administration of A) water, captopril (50 mg kg−1
bw), or AVFQHNCQE (10 mg kg−1 bw) or B) after the administration of water and QVGPLIGRYCG (10 mg kg−1 bw). The data are expressed as the mean
± SEM. All of the experimental groups include a minimum of six animals. Different letters represent significant differences (p < 0.05). p was estimated
by two-way ANOVA.
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hydrophilic membranes with 3 and 10 kDa cut-off values and
ACEI activity of the different obtained fractions was measured.
The results showed that the<3 KDa fraction presented the high-
est ACEI activity. This finding attributes the highest ACEI activity
to small peptides present in this hydrolysate. Similar results were
reported by other authors for hydrolysates obtained from other
protein sources.[25–27] Subsequently, the <3 kDa fraction was
subjected to a two-step RP-HPLC analysis resulting in obtaining
of two subfractions (F3.3 and F6.6) selected according to their
high ACEI activity. The subsequent analysis of subfractions F3.3
and F6.6 by mass spectrometry allowed the selection of eight
peptides (LSETVV, LSGPVKF, AVKILP, VRWEPAPGPV, VGKP-
GARAPMY, QVGPLIGRYCG, LGIHPDWQFV, AVFQHNCQE),
which were subsequently synthesized. As far as we know, none of
these peptides had been previously identified to have any bioactiv-
ity (search carried out in the BIOPEP database as of October 2018,
http://www.uwm.edu.pl/biochemia/index.php/pl/biopep).
The ACEI activity, expressed as the IC50 value, was lower than
100 µm for five of these identified amino acid sequences, indicat-
ing their potential roles as ACE inhibitors. This finding is based
on the fact that all the selected peptides comprised between 6–11
amino acids; it has been previously reported that peptides pre-
senting high ACEI activity are short in length and comprising
3–12 amino acids.[6] It has also been previously reported that the
amino acid composition of the three consecutive C-terminal po-
sitions plays an important role in ACE competitive inhibition.[28]
However, the amino acid residues required for ACE inhibition at
the C-terminal position can be different depending on the pep-
tide size.[29] In general, the presence of hydrophobic aromatic
amino acids (Tyr, Phe, or Try), or amino acids with hydropho-
bic branched side chains (Val, Leu, or Ile) lead to an increase in
ACE inhibitory activity.[14] Additionally, many identified ACE in-
hibitors contain Pro at the C-terminal end. In fact, Pro has a rigid
ring structure that can lock the carboxyl group into a favorable
conformation, making it able to interact with positively charged
residues in the active site of the enzyme.[30] Regarding the N-
terminal position, the presence of branched aliphatic amino acids
such as Gly, Val, Leu, and Ile has been reported as good ACE
substrates.[31] Thus, the presence of the Pro residue at AVKILP C-
terminus, the Tyr residue at the C-terminus and the Val residue
at the N-terminus in VGKPGARAPMY, and the Phe residue at
the C-terminus and Leu at the N-terminus in LSGPVKF may
contribute to their ACEI activity. Regarding the peptide AVFQH-
NCQE, the presence of glutamic acids in its sequence may con-
tribute to its ACEI effect. Indeed, it is known that glutamic acid
may cause a net negative charge, and the interaction of nega-
tively charged peptides with ACE could chelate zinc atoms, which
is a component of the ACE active center.[32] However, the pep-
tide sequence for QVGPLIGRYCG, one of the most potent ACE
inhibitors identified in the Hpp11, did not have any particular
structural features that could be responsible for its activity. Nev-
ertheless, the presence of Tyr at the third position before the final
position at the C-terminus or its conformation in solution could
highly favor its ability to inhibit ACE.[30] In this sense, peptide
conformation, that is the structure adopted in the specific envi-
ronment of the binding site, has been suggested to enhance the
inhibitory ability of long-chain peptides.[33,34]
Additionally, two of the peptides, AVKILP and QVGPLI-
GRYCG, stood out for their high ACEI activities, showing IC50
values as low as 7.06 and 11.01 µm, respectively. Although the
ACEI activity of the drug captopril is higher than that pre-
sented by these peptides, the interest in dietary bioactive com-
pounds is increasing significantly because they present high tis-
sue affinity, specificity, and efficiency in promoting these health
effects.[35] Moreover, the ACEI values of chicken foot-derived pep-
tides are similar than those observed for known antihyperten-
sive peptides, such as the fermented milk-derived peptides IPP,
VPP, and LHLPLP, which showed similar IC50 values (5, 9, and
5.5 µm, respectively).[25,36] Other byproduct chicken-derived pep-
tides have been reported to exert high ACEI activities, but their
activities ranged from 34 to 254 µm.[37,38]
Many peptides that present ACEI activities in vitro do not
exhibit antihypertensive properties. In fact, after their oral ad-
ministration, the peptides may be susceptible to degradation
by gastrointestinal enzymes and by brush border, blood serum,
and/or intracellular peptidases before being transferred into the
bloodstream.[14] Additionally, even though some peptides are
resistant to digestive enzymes, large peptides (>6 amino acid
residues) may not be absorbed into small intestinal epithelial
cells.[13] Therefore, testing the in vivo antihypertensive effects of
the peptides is necessary for validation. To assess their effects in
vivo, the ACEI peptides identified inHpp11were administered to
SHR, an experimental animal model that best mimics essential
hypertension in humans.[39]
The VGKPGARAPMY, LSGPVKF, and AVKILP peptides se-
quences did not exhibit BP-lowering effects. Interestingly, the
AVKILP peptide, which showed the most potent ACEI activity,
did not present antihypertensive effects when administered to
SHR, suggesting that modifications incurred during gastroin-
testinal digestion could inactivate this peptide. In contrast, the
AVFQHNCQE and QVGPLIGRYCG peptides decreased BP af-
ter their oral administration (−25.07 and−10.94 mmHg of SBP
at 6 h post-administration, respectively), with AVFQHNCQE be-
ing the most active peptide. Interestingly, this peptide was also
able to reduceDBP, suggesting its huge potential as an antihyper-
tensive agent. Our findings agree with those demonstrating the
potential antihypertensive properties of bioactive peptides from
chicken by products including chicken bone.[39] Furthermore, the
ACEI peptides IKW, LKP, and IVGRPRHQG, which were iso-
lated from chicken muscle, showed similar antihypertensive ef-
fects as AVFQHNCQE but needed to be administered at a higher
dose of 60 mg kg−1 bw.[40]
5. Conclusions
Novel ACEI peptides have been identified in the chicken foot
hydrolysate Hpp11. Moreover, the antihypertensive properties
of the QVGPLIGRYCG and AVFQHNCQE peptides have been
demonstrated in this study for the first time. The potential of
these peptides for use in functional foods to mitigate hyperten-
sion appears to merit further clinical studies in humans.
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